Business Context and Reporting Period
This Form 8-K was filed by Aquestive Therapeutics, Inc. on March 4, 2026, reporting events occurring on March 3, 2026. The filing primarily addresses the entry into material definitive agreements with RTW Investments, LP and the disclosure of financial results for the quarter and fiscal year ended December 31, 2025.
Key Financial Metrics and Agreements
The filing references financial results for the period ended December 31, 2025, in a press release (Exhibit 99.1), but the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it details the following financial commitments and instruments:
- Warrant Issuance: Issuance of a warrant to purchase up to 375,000 shares of common stock at an exercise price of $4.00 per share, expiring March 3, 2029.
- Share Purchase Commitment: RTW-affiliated funds committed to purchase at least $5,000,000 of common stock within 90 days of the agreement's effective date.
- Marketing Approval Deadline: Extended to June 30, 2027, via Amendment No. 1 to the Purchase and Sale Agreement.
Material Changes
Material changes reported in this filing include:
- Extension of the Marketing Approval Deadline for the underlying asset in the Purchase and Sale Agreement from its original date to June 30, 2027.
- Issuance of unregistered equity securities (warrants) to RTW Investments, LP.
- Securing a commitment for future capital infusion of not less than $5,000,000.
Guidance, Outlook, and Risks
The filing incorporates by reference an investor presentation (Exhibit 99.2) containing management commentary and outlook, but the specific content of that presentation is not detailed in the text of this 8-K. The filing notes that the warrant issuance relies on the Section 4(a)(2) exemption from registration. No specific risks or contingencies are described in the body of this report beyond the standard incorporation of exhibits.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and FY 2025 financial metrics (revenue, net loss, cash position) which are not listed in the 8-K text.
- Examine Exhibit 10.1 to understand the specific terms and conditions of the extended Marketing Approval Deadline.
- Verify the pricing mechanism for the $5,000,000 share purchase commitment under Rule 415(a)(4) as referenced in Exhibit 10.3.
- Assess the dilution impact of the 375,000 warrants issued at a $4.00 exercise price.